Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis

Cortexyme Inc CRTX has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection. 

  • The SAD trial was designed to evaluate the safety and pharmacokinetics of COR588 in healthy volunteers.
  • In the SAD portion of the Phase 1 trial, preliminary results indicate COR588 was well-tolerated across all four cohorts in the dose range from 25 mg to 200 mg with no serious adverse events. 
  • No clinically significant findings were observed on other safety measures, including vital signs, laboratory findings, telemetry, or ECGs. 
  • Related: Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND.
  • COR588 exhibited an 11-to-12-hour half-life consistent with once-daily dosing and a dose-proportional pharmacokinetic profile.
  • The Company will share the complete data set from the COR588 Phase 1 trial in Q2 of 2022 once the multiple ascending dosing phase is complete.
  • Price Action: CRTX shares are up 7.76% at $4.58 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!